Rudi Scheerlinck | Executive Director,Integrated Medical Safety
Novartis Oncology

Rudi Scheerlinck is a certified GP (VUB, Brussels) who holds a Post-graduate Program in Pharmacology and Pharmaceutical Medicine (ULB, Brussels). During 14 years of pharmacovigilance experience, he has gained experience in a broad area of interests, including signal detection, medical analysis, interpretation of safety and epidemiological data, management of safety issues, people management, and general management. He has set up and led medico-scientific teams covering a variety of medicinal products (small molecules, antibodies, and vaccines) across several therapeutic areas (pre- and post-marketing). He acquired experience in developing and maintaining a pharmacovigilance system with close contacts with QA, IT, and Epidemiology. At UCB he occupied positions including Deputy EU QPPV, Head Medical Evaluation, and Director in a Safety Evaluation and Risk Management group. In between, he was Head of Safety Evaluation and Risk Management for the pediatric vaccines at GSK Biologicals. Currently he is working within Integrated Medical Safety at Novartis Oncology.